Antimicrobial-resistant invasive Escherichia coli, Spain

Emerging Infectious Diseases

Volumn 11, Issue 4, 2005, Pages 546-553

  Oteo, Jesús ^a,d   Lázaro, Edurne ^b   De Abajo, Francisco J ^b   Baquero, Fernando ^c   Campos, José ^a,d  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b Agencia Espanola del Medicamento   (Spain)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; CEFOTAXIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; COTRIMOXAZOLE; GENTAMICIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TOBRAMYCIN;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CHILD; COMMUNITY; COMMUNITY ONSET INFECTION; DRUG USE; ENZYME SYNTHESIS; ESCHERICHIA COLI; EUROPEAN ANTIMICROBIAL RESISTANCE SURVEILLANCE SYSTEM; EUROPEAN UNION; FEMALE; GRAM NEGATIVE INFECTION; HUMAN; INVASIVE ESCHERICHIA COLI; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATICS; MULTIDRUG RESISTANCE; NONHUMAN; PUBLIC HEALTH SERVICE; SPAIN;

EID: 16244415869     PISSN: 10806040     EISSN: None     Source Type: Journal    
DOI: 10.3201/eid1104.040699     Document Type: Article

References (35)

1. Williams RJ, Heymann DL. Containment of antimicrobial resistance. Science. 1998;279:1153-4.
2. Karlowsky JA, Jones ME, Draghi DC, Thornsbeny C, Sahm DF, Volturo GA. Prevalence of antimicrobial susceptibilities of bacteria isolated from blood cultures of hospitalized patients in the United States in 2002. Ann Clin Microbiol Antimicrob. 2004;3:7.
3. Richet HM, Mohammed J, McDonald LC, Jarvis WR, and INSPEAR. Building communication networks: International Network for the Study and Prevention of Emerging Antimicrobial Resistance. Emerg Infect Dis. 2001;7:319-22.
4. Thamdrup V, Borge K, editors. The microbial threat. Recommendations of European Union Conference on The Microbial Threat, Copenhagen 1998. Denmark: Ministry of Health and Ministry of Food, Agriculture and Fisheries; 1998.
5. Diekema DJ, Pfaller MA, Jones RN, Doern GV, Winokur PL, Gales AC, et al. Survey of bloodstream infections due to gram-negative bacilli: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, and Latin America for the SENTRY Antimicrobial Surveillance Program, 1997. Clin Infect Dis. 1999;29:595-607.
6. Reacher MH, Shah A, Livermore DM, Wale MC, Graham C, Johnson AP, et al. Bacteraemia and antibiotic resistance of its pathogens reported in England and Wales between 1990 and 1998: trend analysis. BMJ. 2000;320:213-6.
7. Fluit AC, Jones ME, Schmitz FJ, Acar J, Gupta R, Verhoef J. Antimicrobial susceptibility and frequency of occurrence of clinical blood isolates in Europe from the SENTRY antimicrobial surveillance program, 1997-1998. Clin Infect Dis. 2000;30:454-60.
8. Lark RL, Saint S, Chenoweth C, Zemencuk JK, Lipsky BA, Plorde JJ. Four-year prospective evaluation of community-acquired bacteraemia: epidemiology, microbiology and patient outcome. Diagn Microbiol Infect Dis. 2001;41:15-22.
9. Sahm DF, Thornsberry C, Mayfield DC, Jones ME, Karlowsky JA. Multidrug-resistant urinary tract isolates of Escherichia coli: prevalence and patient demographics in the United States. Antimicrob Agents Chemother. 2001;45:1402-6.
10. Garau J, Xercavins M, Rodríguez-Carballeira M, Gómez-Vera JR., Coll I, Vidal D, et al. Emergence and dissemination of quinolone-resistant Escherichia coli in the community. Antimicrob Agents Chemother. 1999;43:2736-41.
11. Goettsch W, Van Pelt W, Nagelkerke N, Hendrix MGR, Buiting AGM, Petit PL, et al. Increasing resistance to fluoroquinolones in Escherichia coli from urinary tract infections in the Netherlands. J Antimicrob Chemother. 2000;46:223-8.
12. Eckert C, Gautier V, Saladin-Allard M, Hidri N, Verdet C, Ould-Hocine Z, et al. Dissemination of CTX-M-type beta-lactamases among clinical isolates of Enterobacteriaceae in Paris, France. Antimicrob Agents Chemother. 2004;48:1249-55.
13. Walther-Rasmussen J, Hoiby N. Cefotaximases (CTX-M-ases), an expanding family of extended spectrum beta-lactamases. Can J Microbiol. 2004;50:137-65.
14. Sherley M, Gordon DM, Collignon PJ. Evolution of multi-resistance plasmids in Australian clinical isolates of Escherichia coli. Microbiology. 2004;150:1539-46.
15. Oteo J, Campos J, Baquero F. Antibiotic resistance in 1962 invasive isolates of Escherichia coli in 27 Spanish hospitals participating in the European Antimicrobial Resistance Surveillance System (2001). J Antimicrob Chemother. 2002;50:945-52.
16. Cars O, Mölstad S, Melander A. Variation in antibiotic use in the European Union. Lancet. 2001;357:1851-3.
17. Ruiz-Bremon A, Ruiz-Tovar M, Pérez-Gorricho B, Diaz de Torres P, López-Rodriguez R. Non-hospital consumption of antibiotics in Spain: 1987-1997. J Antimicrob Chemother. 2000;45:395-400.
18. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing-14th informational supplement, approved standard M100-S14. Wayne (PA): The Committee; 2004.
19. Lázaro Bengoa E, Madurga Sanz M, de Abajo Iglesias FJ. Evolución del consumo de antibióticos en España, 1985-2000. Med Clin. 2002;118:561-8.
20. WHO Collaborating Centre for Drug Statistics Methodology. Anatomical therapeutic chemical (ATC) classification index including defined daily doses (DDDs) for plain substances. Oslo: The Centre; 1999.
21. Goosens H, Sprenger MJW. Community acquired infections and bacterial resistance. BMJ. 1998;317:654-7.
22. Centers for Disease Control. Guidelines for evaluating surveillance systems. MMWR Morb Mortal Wkly Rep. 1988;37(S5):1-18.
23. Bronzwaer S, Buchholz U, Courvalin P, Snell J, Comaglia G, de Neeling A, et al. Comparability of antimicrobial susceptibility test results from 22 European countries and Israel: an external quality assurance exercise of the European Antimicrobial Resistance Surveillance System (EARSS) in collaboration with the United Kingdom National External Quality Assurance Scheme (UK NEQAS). J Antimicrob Chemother. 2002;50:953-64.
24. Livermore DM, Threlfall EJ, Reacher MH, Johnson AP, James D, Cheasty T, et al. Are routine sensitivity test data suitable for the surveillance of resistance? Resistance rates amongst Escherichia coli from blood and CSF from 1991-1997, as assessed by routine and centralized testing. J Antimicrob Chemother. 2000;45:205-11.
25. Sahm DF, Marsilio MK, Piazza G. Antimicrobial resistance in key bloodstream bacterial isolates: electronic surveillance with The Surveillance Network Database-USA. Clin Infect Dis. 1999;29:259-63.
26. Smith Moland E, Black JA, Hossain A, Hanson ND, Thomson KS, Pottumarthy S. Discovery of CTX-M-like extended-spectrum β-lactamases in Escherichia coli isolates from five U.S. states. Antimicrob Agents Chemother. 2003;47:2382-3.
27. Diekema DJ, BootsMiller BJ, Vaughn TE, Woolson RF, Jankey JW, Ernst EJ, et al. Antimicrobial resistance trends and outbreak frequency in United States hospitals. Clin Infect Dis. 2004;38:78-85.
28. Karlowsky JA, Kelly LJ, Thomsberry C, Jones ME, Sahm DF. Trends in antimicrobial resistance among urinary tract infection isolates of Escherichia coli from female outpatients in the United States. Antimicrob Agents Chemother. 2002;46:2540-5.
29. Bolon MK, Wright SB, Gold HS, Carmeli Y. The magnitude of the association between fluoroquinolone use and quinolone-resistant Escherichia coli and Klebsiella pneumoniae may be lower than previously reported. Antimicrob Agents Chemother. 2004;48:1934-40.
30. Alos JI, Gómez-Garcés JL, García-Bermejo I, García-Gómez JJ, Gonzalez-Palacios R, Padilla B. The prevalence of Escherichia coli susceptibility to quinolone and other antibiotics in community-acquired bacteriurias in Madrid. Med Clin (Barc). 1993;101:87-90.
31. Enne VI, Livermore DM, Stephens P, Hall LCM. Persistence of sulphonamide resistance in Escherichia coli in UK despite national prescribing restriction. Lancet. 2001;357:1325-8.
32. Austin DJ, Kristinsson KG, Anderson RM. The relationship between the volume of antimicrobial consumption in human communities and the frequency of resistance. Proc Natl Acad Sci U S A. 1999;96:1152-6.
33. Aracil B, Miñambres M, Oteo J, Gómez-Garcés JL, Alós JI. High prevalence of erythromycin-resistant and clindamycin-susceptible (M-phenotype) viridans group streptococci from pharyngeal samples: a reservoir of mef genes in commensal bacteria. J Antimicrob Chemother. 2001;48:592-4.
34. Cheong HJ, Yoo CW, Sohn JW, Kim WJ, Kim MJ, Park SC. Bacteremia due to quinolone-resistant Escherichia coli in a teaching hospital in South Korea. Clin Infect Dis. 2001;33:48-53.
35. Sherley M, Gordon DM, Collignon PJ. Evolution of multi-resistance plasmids in Australian clinical isolates of Escherichia coli. Microbiology. 2004;150:1539-46.